Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
(2011) In Quarterly Journal of Nuclear Medicine and Molecular Imaging 55(2). p.126-154- Abstract
- Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy. The therapeutic effect is determined by the radiopharmaceutical, the radiation absorbed dose and previous treatments. There are currently two approved radiopharmaceuticals for the treatment of B-cell lymphoma - the 90Y-labeled ibritumomab and the 131I-labeled tositumomab. Both are directed against CD20, albeit not against the same epitope. This paper summarizes current results of dose-responses for normal tissues and tumours of [131I]tositumomab and [90Y]ibritumomab tiuxetan, discusses them in the context of dosimetry methods used and highlights the assumptions being made in the different dosimetry methodologies. Moreover, we wish to point... (More)
- Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy. The therapeutic effect is determined by the radiopharmaceutical, the radiation absorbed dose and previous treatments. There are currently two approved radiopharmaceuticals for the treatment of B-cell lymphoma - the 90Y-labeled ibritumomab and the 131I-labeled tositumomab. Both are directed against CD20, albeit not against the same epitope. This paper summarizes current results of dose-responses for normal tissues and tumours of [131I]tositumomab and [90Y]ibritumomab tiuxetan, discusses them in the context of dosimetry methods used and highlights the assumptions being made in the different dosimetry methodologies. Moreover, we wish to point at the possibility of performing low-cost therapy bremsstrahlung imaging for [90Y]ibritumomab tiuxetan to confirm biodistribution, and possibly also for dosimetric calculations. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1884189
- author
- Sjögreen Gleisner, Katarina LU ; Dewaraja, Y K ; Chiesa, C ; Tennvall, Jan LU ; Lindén, Ola LU ; Strand, Sven-Erik LU and Ljungberg, Michael LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Lymphoma, Dosimetry, Antibodies, monoclonal, Radioimmunotherapy
- in
- Quarterly Journal of Nuclear Medicine and Molecular Imaging
- volume
- 55
- issue
- 2
- pages
- 126 - 154
- publisher
- Edizioni Minerva Medica
- external identifiers
-
- pmid:21386787
- wos:000291627700003
- scopus:79957658685
- ISSN
- 1824-4785
- language
- English
- LU publication?
- yes
- id
- 561db951-2dba-47ce-85e2-5501b3c27db7 (old id 1884189)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21386787?dopt=Abstract
- date added to LUP
- 2016-04-01 10:30:33
- date last changed
- 2022-03-19 21:27:47
@article{561db951-2dba-47ce-85e2-5501b3c27db7, abstract = {{Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy. The therapeutic effect is determined by the radiopharmaceutical, the radiation absorbed dose and previous treatments. There are currently two approved radiopharmaceuticals for the treatment of B-cell lymphoma - the 90Y-labeled ibritumomab and the 131I-labeled tositumomab. Both are directed against CD20, albeit not against the same epitope. This paper summarizes current results of dose-responses for normal tissues and tumours of [131I]tositumomab and [90Y]ibritumomab tiuxetan, discusses them in the context of dosimetry methods used and highlights the assumptions being made in the different dosimetry methodologies. Moreover, we wish to point at the possibility of performing low-cost therapy bremsstrahlung imaging for [90Y]ibritumomab tiuxetan to confirm biodistribution, and possibly also for dosimetric calculations.}}, author = {{Sjögreen Gleisner, Katarina and Dewaraja, Y K and Chiesa, C and Tennvall, Jan and Lindén, Ola and Strand, Sven-Erik and Ljungberg, Michael}}, issn = {{1824-4785}}, keywords = {{Lymphoma; Dosimetry; Antibodies; monoclonal; Radioimmunotherapy}}, language = {{eng}}, number = {{2}}, pages = {{126--154}}, publisher = {{Edizioni Minerva Medica}}, series = {{Quarterly Journal of Nuclear Medicine and Molecular Imaging}}, title = {{Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.}}, url = {{http://www.ncbi.nlm.nih.gov/pubmed/21386787?dopt=Abstract}}, volume = {{55}}, year = {{2011}}, }